News & Articles

Consortium formed to lower costs of cell and gene therapies through process development and manufacturing collaborations

Top talks presenting the latest technologies, research and applications are now available on demand

Novel chip-based diagnostic technology can detect individual viral antigens in nasal swab samples to identify the viruses that cause COVID-19 and flu with a single test

Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India

The new Access AMH Advanced aims to provide validated cut-offs for the assessment of ovarian reserve and ovarian response as an aid for women undergoing in vitro fertilization (IVF)

Watch world-leading clinical scientists and healthcare professionals online, June 22-23, to discover the latest tools and techniques advancing COVID-19 diagnostic testing, cardiovascular treatments, point-of-care and more

Collaboration follows successful acquisition and commercialization of Oxsed, an Oxford University Spin-out, to scale OxLAMP rapid COVID-19 test globally

A new study shows that the less-invasive saliva test for COVID-19 gives just as accurate results as those of the nasopharyngeal specimen.

The fast time-to-result includes a pretreatment process to inactivate the virus as a safeguard for laboratory staff handling the samples

New findings pave way to potentially improved assessment of measurable residual disease in AML patients

New service reduces project time from months to weeks for biopharma customers

The Allplex SARS-CoV-2 Master Assay can detect a total of 10 targets including four coronavirus genes

Seegene’s new product filters COVID-19 and variants during primary PCR testing in 1 hr 55 min

Dr. Boye Schnack Nielsen shares tips for running successful in situ hybridization assays as he provides insights on how RNA detection methods have evolved over time

The antigen test is used to detect the nucleocapsid protein antigen in SARS-CoV-2

Seegene can produce 300,000 variant diagnostic test kits, capable of testing 30 million people every month

Highly complementary cell counting and analysis capabilities bolster preclinical portfolio and enhance QA/QC capabilities in cell and gene therapy and biologics manufacturing

The Simplexa™ SARS-CoV-2 Variants Direct assay aims to enable detection of four mutations associated with virus variants without requiring upfront RNA extraction

The availability of an International Standard (IS) for antibodies facilitates the standardization of SARS-CoV-2 serological methods